RhumbLine Advisers’s Scinai Immunotherapeutics SCNI Stock Holding History

RhumbLine Advisers’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.91K	Sell	1,349 -2	-0.1%	-$5	﹤0.01%	3931
2026 Q2	$3.42K	Buy	1,351 +1,163	+619%	+$5.72K	﹤0.01%	3986
2026 Q1	$1.04K	Hold	188	–	–	﹤0.01%	3975
2025 Q4	$1.34K	Sell	188 -167	-47%	-$1.9K	﹤0.01%	4014
2025 Q3	$4.49K	Buy	355 +7	+2%	+$122	﹤0.01%	3922
2025 Q2	$7.98K	Buy	348 +191	+122%	+$4.81K	﹤0.01%	3890
2025 Q1	$4.17K	Sell	157 -8	-5%	-$274	﹤0.01%	3927
2024 Q4	$5.5K	Hold	165	–	–	﹤0.01%	3940
2024 Q3	$5.85K	Buy	165 +51	+45%	+$1.95K	﹤0.01%	3959
2024 Q2	$3.24K	Buy	114 +47	+70%	+$1.95K	﹤0.01%	4148
2024 Q1	$3.44K	Buy	67 +14	+26%	+$722	﹤0.01%	4031
2023 Q4	$3.08K	Buy	53 +18	+51%	+$1.24K	﹤0.01%	4050
2023 Q3	$3.08K	Hold	35	–	–	﹤0.01%	4060
2023 Q2	$4.76K	Buy	+35	New	+$6.04K	﹤0.01%	4097

Other funds holding SCNI

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

RhumbLine Advisers's SCNI Position: Q3 2026 in Review

RhumbLine Advisers reduced its Scinai Immunotherapeutics (SCNI) stake by 0.15% in Q3 2026, selling an estimated $5 and leaving 1,349 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #3931.

RhumbLine Advisers first reported a position in SCNI in Q2 2023 and has held it in 14 quarters since. The position peaked at $7.98K in Q2 2025. 2 funds tracked by Wall St. Rank hold SCNI as of Q3 2026.

RhumbLine Advisers held 1,349 shares of Scinai Immunotherapeutics worth $1.91K as of Q3 2026.
RhumbLine Advisers sold 2 Scinai Immunotherapeutics shares in Q3 2026, an estimated $5.
Scinai Immunotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3931 holding.
RhumbLine Advisers first reported a position in Scinai Immunotherapeutics in Q2 2023 and has held it in 14 quarters since.
RhumbLine Advisers's Scinai Immunotherapeutics position peaked at $7.98K in Q2 2025.
2 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.